**Supplemental Data**

**Sample handling and analysis of the atherosclerotic plaque**

After removal of the atherosclerotic plaque during CEA, the plaque was immediately processed in the laboratory. The carotid plaque was cut in cross-sectional segments of 5mm. The section with the largest plaque burden was identified as the culprit lesion and subsequently immunohistochemically stained: Hematoxylin-Eosin (HE) staining for general overview of fat and calcification, picro-sirius red and elastin von Gieson for collagen content, CD68 for macrophages, α-actin for smooth muscle cells (SMC) and CD34 for microvessels. Intraplaque hemorrhage (IPH) was determined by HE and Mallory’s phosphotungstic acid-hematoxylin staining. Histological slides were analyzed at 40x magnification and were analyzed by a dedicated experienced technician. Previous studies showed excellent intra-observer and inter-observer variability.1,2 Semi-quantitative analysis of collagen, SMC, macrophages, calcification content was performed and for the present analyses grouped in two categories (no/minor staining vs. moderate/heavy staining). Lipid core was determined by polarized light and its size was estimated as more or less than 10% of the total plaque area. IPH was defined as hemorrhage within the plaque tissue or plaque bleeding at the luminal side of the plaque due to plaque disruption.3 Computerized analysis was performed for quantification of macrophages, SMC and microvessels (AnalySiS version 3.2, Soft Imaging GmbH, Munster, Germany), defined as the average of three hotspots. To assess the overall vulnerability of a plaque, a vulnerability score was created ranging from 0-5 with 1 point for plaque characteristics that are considered hallmarks of a vulnerable plaque (moderate/heavy macrophages, no/minor collagen, no/minor SMC, lipid core>10% and presence of IPH), based on a previous publication in the AE4. A more detailed description of the standardized protocol for carotid plaque processing and analysis of plaque characteristics can be found in previous Athero-Express publications.3,5

**References**

1. Vrijenhoek JEP, Nelissen BGL, Velema E, Vons K, Vries J-PPM de, Eijkemans MJC, Ruijter HM den, Borst GJ de, Moll FL, Pasterkamp G. High Reproducibility of Histological Characterization by Whole Virtual Slide Quantification; An Example Using Carotid Plaque Specimens. PLoS One 2014;9:e115907.

2. Hellings WE, Pasterkamp G, Vollebregt A, Seldenrijk CA, Vries JPPM De, Velema E, Kleijn DPV De, Moll FL. Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens. J Vasc Surg 2007;46:1147–1154.

3. Hellings WE, Peeters W, Moll FL, Piers SRD, Setten J van, Spek PJ Van der, Vries JPPM de, Seldenrijk KA, Bruin PC De, Vink A, Velema E, Kleijn DP V de, Pasterkamp G. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010;121:1941–1950.

4. Verhoeven B, Hellings WE, Moll FL, Vries JP de, Kleijn DPV de, Bruin P de, Busser E, Schoneveld AH, Pasterkamp G. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg 2005;42:1075–1081.

5. Verhoeven BAN, Velema E, Schoneveld AH, Vries JPPM de, Bruin P de, Seldenrijk CA, Kleijn DP V de, Busser E, Graaf Y van der, Moll F, Pasterkamp G. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol 2004;19:1127–1133.

|  |  |
| --- | --- |
|  | **sCVE** |
| **MetaGRS (as continuous measure)** |  |
| univariate | age, sex, PC1-4, genotype array |
| traditional risk factors | age, sex, hypertension, diabetes, hypercholesterolemia, BMI and smoking |
| additional confounders (p<0.20) | none |
| **MetaGRS (top 20% vs. remaining 80%)** |  |
| univariate | age, sex, PC1-4, genotype array |
| traditional risk factors | age, sex, hypertension, diabetes, hypercholesterolemia, BMI and smoking |
| additional confounders (p<0.20) | none |
| **MetaGRS (top 20% vs. bottom 20%)** | age, sex, PC1-4, genotype array |
| traditional risk factors | age, sex, hypertension, diabetes, hypercholesterolemia, BMI and smoking |
| additional confounders (p<0.20) | none |
| **FHx** |  |
| traditional risk factors | age, sex, hypertension, diabetes, hypercholesterolemia, BMI and smoking |
| additional confounders (p<0.20) | history of CAD, history of PAD, cerebrovascular symptoms and eGFR |
| **Table S1. Overview of confounders used in multivariable analyses.**Selected confounders for multivariable analysis of composite secondary cardiovascular events (sCVE) were based on literature and additional confounders were identified through association of p<0.20 with MetaGRS or positive family history (FHx) and sCVE. *CAD*, coronary artery disease; *PAD,* peripheral artery disease; *eGFR,* estimated glomerular filtration rate; *BMI,* body mass index. |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Presence of lipid core ≥10%** | **Moderate/heavy** **calcifications** | **Moderate/heavy** **collagen** | **Presence of IPH** | **Moderate/heavy macrophages** | **Moderate/heavy SMC** | **Mean number of microvessels per hotspot** | **% of positive macrophage staining per plaque** | **% of positive SMC staining per plaque** |
| **MetaGRS (continuous)** |  |  |  |  |  |  |  |  |  |
| based on literature | *Age, sex, surgery year, cerebrovascular symptoms, PC 1-4 and genotype array* |
| additional confounders (p<0.20) | LLD use | HDL | HC | LLD use | LLD use | HC | none | LLD use | HC |
| **MetaGRS****(top 20% vs. remaining 80%)** |  |  |  |  |  |  |  |  |  |
| based on literature | *Age, sex, surgery year, cerebrovascular symptoms, PC 1-4 and genotype array* |
| additional confounders (p<0.20) | CL stenosisdiabetes | None | CL stenosis | BMI | None | CL stenosis | BMI | CL stenosisdiabetes | CL stenosis |
| **MetaGRS****Top 20% vs. lowest 20%** |  |  |  |  |  |  |  |  |  |
| based on literature | *Age, sex, surgery year, cerebrovascular symptoms, PC 1-4 and genotype array* |
| additional confounders (p<0.20) | LLD use diabetesCL stenosis | TC | HCCL stenosis | LDLTC | LLD use | CL stenosisHC | none | LLD use diabetesCL stenosis | CL stenosisHC |
| **FHx** |  |  |  |  |  |  |  |  |  |
| based on literature | *Age, sex, surgery year and cerebrovascular symptoms* |
| additional confounders (p<0.20) | history of strokeLLD use PADeGFR | hypertensionCADhistory of strokePADTC | hypertensionHCPAD | BMIhypertensionCADhistory of strokeLDLTC | hypertensionhistory of strokeTGPADIpsilateral stenosis degree | HChistory of strokeeGFR | BMIIpsilateral stenosis degreeHTCADTG | hypertensionLLD use PADIpsilateral stenosis degree | HChistory of strokeeGFR |
| **Table S2. Overview of confounders added to multivariable models of histological plaque characteristics.**Confounders were selected based on literature and those with association of p<0.20 with MetaGRS or FHx and the plaque characteristic of interest.*SMC,* smooth muscle cells; *FHx,* positive family history. *HC,* hypercholesterolemia; *CL stenosis,* contralateral carotid artery stenosis of 50-100%; *TC,* total cholesterol blood levels, *TG,* triglycerides blood levels, *PAD,* peripheral artery disease; eGFR, estimated glomerular filtration rate; *CAD,* coronary artery disease; BMI, body mass index; LLD use, use of lipid-lowering drugs. |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total cohort** |   | **Female cohort** |   | **Male cohort** |   |
|  | **HR (95% CI)** | **p-value** | **HR (95% CI)** | **p-value** | **HR (95% CI)** | **p-value** |
| ***Family History*** |  |  |   |   |   |   |
| Univariate | 1.292 (1.066-1.566) | **0.009\*** | 1.187 (0.822-1.1714) | 0.360 | 1.351 (1.079-1.693) | **0.009\*** |
| Multivariable#  | 1.287 (1.033-1.604) | **0.024\*** | *NA* | *NA* | 1.380 (1.068-1.783) | **0.014\*** |
| Multivariable # +IPH | 1.329 (1.055-1.675) | **0.016\*** | *NA* | *NA* | 1.434 (1.095-1.877) | **0.009\*** |
| Multivariable# including MetaGRS | 1.397 (1.074-1.819) | **0.013\*** | *NA* | *NA* | 1.513 (1.115-2.052) | **0.008\*** |
| Multivariable# including MetaGRS + IPH | 1.400 (1.073-1.826) | **0.013\*** | *NA* | *NA* | 1.514 (1.112-2.062) | **0.008\*** |
| ***MetaGRS* (as continuous measure)** |   |  |   |   |   |   |
| Univariate\*  | 1.686 (1.090-2.608) | **0.019\*** | 0.711 (0.307-1.645) | 0.425 | 2.298 (1.382-3.820) | **0.001\*** |
| Multivariable\* | 1.724 (1.080-2.752) | **0.022\*** | *NA* | *NA* | 2.307 (1.343-3.961) | **0.002\*** |
| Multivariable\* + IPH | 1.736 (1.085-2.777) | **0.021\*** | *NA* | *NA* | 2.307 (1.337-3.983) | **0.003\*** |
| Multivariable including FHx\*\* | 1.525 (0.937-2.483) | 0.090 | *NA* | *NA* | 2.155 (1.227-3.784) | **0.008\*** |
| Multivariable including FHx\*\* + IPH | 1.553 (0.952-2.534) | 0.078 | *NA* | *NA* | 2.204 (1.251-3.882) | **0.006\*** |
| ***MetaGRS (top 20% versus remaining 80%)*** |   |  |   |   |   |   |
| Univariate\* | 1.353 (1.047-1.749) | **0.021\*** | 0.904 (0.540-1.514) | 0.701 | 1.582 (1.178-2.124) | **0.002\*** |
| Multivariable\*\* | 1.370 (1.040-1.805) | **0.025\*** | *NA* | *NA* | 1.605 (1.173-2.196) | **0.003\*** |
| Multivariable \*\* + IPH | 1.392 (1.055-1.836) | **0.019\*** | *NA* | *NA* | 1.614 (1.198-2.249) | **0.002\*** |
| Multivariable including FHx\*\*\* | 1.345 (1.009-1.792) | **0.043\*** | *NA* | *NA* | 1.606 (1.158-2.227) | **0.005\*** |
| Multivariable including FHx\*\*\* + IPH | 1.374 (1.030-1.833) | **0.031\*** | *NA* | *NA* | 1.656 (1.193-2.299) | **0.003\*** |
| ***MetaGRS (top 20% versus bottom 20%)*** |   |  |   |   |   |   |
| Univariate\* | 1.539 (1.086-2.181) | **0.015\*** | 0.778 (0.405-1.492) | 0.449 | 1.988 (1.319-2.996) | **0.001\*** |
| Multivariable\*\* | 1.661 (1.138-2.426) | **0.009\*** | *NA* | *NA* | 2.088 (1.347-3.237) | **0.001\*** |
| Multivariable \*\* + IPH | 1.705 (1.164-2.499) | **0.006\*** | *NA* | *NA* | 2.146 (1.375-3.349) | **0.001\*** |
| Multivariable including FHx\*\*\* | 1.583 (1.066-2.351) | **0.023\*** | *NA* | *NA* | 2.100 (1.322-3.335) | **0.002\*** |
| Multivariable including FHx\*\*\* + IPH | 1.635 (1.097-2.435) | **0.016\*** | *NA* | *NA* | *NA* | *NA* |
| **Table S3.** **Univariate and multivariate Cox-regression analyses for the association of FHx and MetaGRS** **with secondary CVE.** *HR,* hazard ratio. *CI,* confidence interval. HR indicate the risk for secondary CVE for patients with positive FHx versus those without or respectively for patients with MetaGRS in top 20% of the distribution compared to those in the remaining 80% or bottom 20% of the distribution. Multivariable analyses of FHx were corrected for traditional risk factors (age, sex, hypercholesterolemia, diabetes, hypertension, BMI and smoking) and additional confounders with an association of p<0.20 including history of CAD, history of PAOD, presenting cerebrovascular symptoms and eGFR.Univariate analyses of MetaGRS were corrected for age, sex, PC 1-4 and genotype array. Multivariable analyses of MetaGRS were corrected for traditional risk factors (age, sex, diabetes, BMI, smoking, hypertension and hypercholesterolemia).Values indicated as bold\* are statistically significant.*NA;* not available; multivariable analyses could not be performed because of limited power (with respect to sub-analyses of sex differences).  |



**Figure S1. Distribution of MetaGRS in the Athero-Express Biobank.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   | Total genotyped cohort (n=1,319) | Bottom 20% of MetaGRS (n=265) | Top 20% of MetaGRS(n=264) | p-value |
| Age (mean, SD) | 68.7 [9.3] | 70.1 [9.0] | 67.1 [9.7] | **2.370 E-4 \* b** |
| Male sex  | 914 (69.3) | 192 (72.5) | 166 (62.9) | **0.019\* b** |
| BMI (mean, SD) | 26.3 [3.8] | 26.2 [3.7] | 26.7 [4.3] | 0.228 |
| GFR (mean, SD) | 72.3 [20.1] | 71.4 [19.4] | 73.0 [20.2] | 0.471 |
| Smoking  | 456 (35.2) | 95 (36.1) | 97 (37.5) | 0.753 |
| Diabetes  | 303 (23.0) | 64 (24.2) | 48 (18.2) | 0.093 **b** |
| Hypertension  | 921 (72.2) | 190 (74.2) | 192 (74.1) | 0.921 |
| Hypercholesterolemia  | 806 (65.9) | 153 (61.4) | 172 (69.1) | 0.079 **b** |
| History of CAD  | 389 (29.5) | 64 (24.2) | 83 (31.6) | 0.058 **b** |
| History of stroke  | 437 (33.1) | 99 (37.4) | 89 (33.7) | 0.381 |
| PAOD | 270 (20.5) | 50 (18.9) | 54 (20.5) | 0.631 |
| Stenosis ipsilateral |   |   |   | 0.832 |
| Φ 50-70% | 88 (6.8) | 19 (7.3) | 18 (7.0) |   |
| Φ 70-99% | 1,200 (93.2) | 240 (92.7) | 238 (93.0) |   |
| Contralateral stenosis >50%  | 543 (45.4) | 100 (42.9) | 118 (49.4) | 0.160 **b** |
| Symptoms  |   |   |   | **0.047\* b** |
|  Φ Asymptomatic | 178 (13.5) | 25 (9.4) | 43 (16.3) |   |
| Φ Ocular | 203 (15.4) | 32 (12.1) | 40 (15.2) |   |
| Φ TIA | 580 (44.1) | 126 (47.5) | 114 (43.3) |   |
| Φ Stroke | 354 (26.9) | 82 (30.9) | 66 (25.1) |   |
| Total cholesterol, median [IQR] | 4.4 [1.6] | 4.1 [1.8] | 4.4 [1.7] | 0.065 **b** |
| LDL cholesterol, median [IQR] | 2.4 [1.3] | 2.2 [1.4] | 2.5 [1.4] | **0.033\* b** |
| HDL cholesterol, median [IQR] | 1.1 [0.4] | 1.1 [0.4] | 1.1 [0.4] | 0.717 |
| Triglycerides, median [IQR] | 1.5 [1.0] | 1.4 [1.0] | 1.5 [0.9] | 0.837 |
| Lipid lowering drug use  | 999 (75.9) | 190 (71.7) | 204 (77.3) | 0.141 **b** |
| Antiplatelet drug use  | 1,164 (88.5) | 238 (89.8) | 236 (89.4) | 0.875 |
| Surgery year |   |   |   | 0.843 |
| Φ 2002-2003 | 192 (14.6) | 34 (12.8) | 41 (15.5) |   |
| Φ 2004-2005 | 307 (23.3) | 58 (21.9) | 64 (24.2) |   |
| Φ 2006-2007 | 270 (20.5) | 55 (20.8) | 56 (21.2) |   |
| Φ 2008-2009 | 232 (17.6) | 53 (20.0) | 47 (17.8) |   |
| Φ 2010-2011 | 224 (17.0) | 50 (18.9) | 42 (15.9) |   |
| Φ 2012-2013 | 94 (7.1) | 15 (5.7) | 14 (5.3) |   |
| Table S4. Baseline characteristics of genotyped patients (those in the top 20% of MetaGRS distribution compared to those in the bottom 20%).Values are displayed as n (%), unless otherwise specified. Values indicated as bold\* are statistically significant. Values below p<0.20 are indicated by b. *BMI*, Body mass index; *CAD*, coronary artery disease; *PAD,* peripheral artery disease; *eGFR*, estimated glomerular filtration rate; *TIA*, transient ischemic attack*; SD*, standard deviation.When multiple cerebrovascular symptoms occurred in the six months prior to the operation, the most serious symptom counts in the following order: stroke> TIA> ocular. Ocular symptoms include transient or permanent retinal ischemia.History of any stroke includes ipsilateral or contralateral stroke. Antiplatelet drug use includes the use of aspirin, dipyridamole or any ADP-inhibitor. Lipid lowering drug use includes any lipid-lowering drug. Diabetes, hypercholesterolemia and hypertension were defined as diagnosed by a medical doctor or medication use for the specific comorbidity. |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Categorical plaque characteristics | Bottom 20% of MetaGRS (n=262) | Top 20% of MetaGRS(n=261) | Unadjusted OR (95% CI) | Unadjustedp-value |  Adjusted OR(95% CI) | Adjusted p-value |
| Moderate/heavy calcifications | 135/261 (51.7) | 135/261 (51.7) | 1.000 (0.709-1.410) | 1.000 | 0.966 (0.643-1.451) | 0.868 |
| Moderate/heavy collagen  | 208/262 (79.4) | 211/261 (80.8) | 1.096 (0.713-1.684) | 0.677 | 1.256 (0.768-2.055) | 0.363 |
| Presence of lipid core >10% | 188/262 (71.8) | 209/261 (80.1) | 1.582 (1.054-2.374) | **0.026\*** | 1.887 (1.188-2.997) | **0.007\*** |
| Presence of IPH  | 155/262 (58.8) | 160/261 (61.3) | 1.111 (0.783-1.577) | 0.556 | 1.168 (0.759-1.797) | 0.480 |
| Moderate/heavy smooth muscle cells  | 183/260 (70.4) | 185/260 (71.2) | 1.038 (0.711-1.515) | 0.847 | 0.926 (0.596-1.441) | 0.735 |
| Moderate/heavy macrophages  | 139/261 (53.3) | 161/260 (61.9) | 1.427 (1.007-2.023) | **0.045\*** | 1.379 (0.956-1.991) | 0.086 |
| Continuous plaque characteristics |  |  | **Unadjusted beta****(95% CI)** | **Unadjusted****p-value** | **Adjusted beta****(95% CI)** | **Adjusted p-value** |
| Number of macrophages (median, IQR) | 0.3 [0.9] | 0.5 [1.0] | 0.055 (-0.026-0.136) | 0.184 | 0.047 (-0.038-0.132) | 0.277 |
| Number of smooth muscle cells (median, IQR) | 1.3 [2.3] | 1.3 [2.3] | 0.031 (-0.082-0.145) | 0.587 | -0.020 (-0.144-0.104) | 0.751 |
| Microvessels (median, IQR) | 6.7 [9.0] | 7.3 [7.0] | 0.126 (-0.012-0.265) | 0.074 | 0.103 (-0.034-0.240) | 0.141 |
| Table S5. Associations of histological carotid plaque characteristics and MetaGRS (patients in top 20% compared to those in bottom 20% of MetaGRS).Values are displayed as n/total (%), unless otherwise specified. Values indicated as bold\* are statistically significant. *OR,* odds ratio; *IPH,* intraplaque haemorrhage. Unadjusted OR indicates univariate analysis, adjusted OR indicates multivariable analysis. Multivariable analyses were corrected for age, sex, surgery year, cerebrovascular symptoms and additional confounders showing p<0.20 association with MetaGRS and the plaque characteristics of interest. Confounders included in various multivariable models can be found in Supplemental Table S2. |

|  |
| --- |
| **MetaGRS (as continuous measure)** |
| **Female cohort** |  |  |  |  |
| ***Binominal plaque characteristics*** | **Unadjusted OR (95% CI)** | **p-value** | **Adjusted OR (95% CI)** | **p-value** |
| Moderate/heavy calcifications | 0.883 (0.396-1.969) | 0.761 | 0.508 (0.192-1.343) | 0.172 |
| Moderate/heavy collagen  | 2.515(0.921-6.867) | 0.072 | 2.606 (0.910-7.468) | 0.074 |
| Presence of lipid core >10% | 1.664 (0.724-3.823) | 0.230 | 1.822 (0.771-4.305) | 0.172 |
| Presence of IPH  | 0.946 (0.420-2.129) | 0.893 | 0.959 (0.420-2.194) | 0.922 |
| Moderate/heavy smooth muscle cells  | 0.649 (0.245-1.722) | 0.386 | 0.534 (0.192-1.488) | 0.230 |
| Moderate/heavy macrophages  | 2.136 (0.951-4.798) | 0.066 | 2.372 (1.036-5.429) | **0.041\*** |
| ***Continuous plaque characteristics*** | **Unadjusted beta (95% CI)** | **p-value**  | **Adjusted beta (95%CI)** | **p-value**  |
| Number of macrophages  | 0.103 (-0.079-0.285) | 0.267 | 0.160 (0.052-0.268) | **0.004\*** |
| Number of smooth muscle cells | -0.014 (-0.247-0.220) | 0.909 | 0.016 (-0.116-0.149) | 0.808 |
| Vessel density  | 0.289 (-0.026-0.603) | 0.072 | 0.305 (-0.007-0.617) | 0.055 |
|  **Male cohort** |  |  |  |  |
| ***Binominal plaque characteristics*** | **Unadjusted OR (95% CI)** | **p-value** | **Adjusted OR (95% CI)** | **p-value** |
| Moderate/heavy calcifications | 0.929 (0.537-1.606) | 0.793 | 0.935 (0.500-1.750) | 0.833 |
| Moderate/heavy collagen  | 0.837 (0.424-1.649) | 0.606 | 0.938 (0.456-1.928) | 0.862 |
| Presence of lipid core >10% | 1.859 (0.957-3.611) | 0.067 | 1.927 (0.975-3.809) | 0.059 |
| Presence of IPH  | 2.05 (1.135-3.702) | **0.017\*** | 2.277 (1.242-4.176) | **0.008\*** |
| Moderate/heavy smooth muscle cells  | 1.211 (0.671-2.184) | 0.525 | 1.265 (0.681-2.350) | 0.456 |
| Moderate/heavy macrophages  | 1.204 (0.693-2.092) | 0.510 | 1.235 (0.703-2.167) | 0.463 |
| ***Continuous plaque characteristics*** | **Unadjusted beta (95% CI)** | **p-value**  | **Adjusted beta (95%CI)** | **p-value**  |
| Number of macrophages | 0.022 (-0.103-0.147) | 0.733 | 0.013 (-0.111-0.137) | 0.839 |
| Number of smooth muscle cells | -0.040 (-0.206-0.125) | 0.635 | -0.042 (-0.214-0.130) | 0.635 |
| Vessel density  | 0.091 (-0.120-0.302) | 0.397 | 0.082 (-0.126-0.291) | 0.439 |
| **Table S6. Sex-stratified associations of MetaGRS with histological carotid atherosclerotic plaque characteristics.**Values are displayed as n/total (%), unless otherwise specified. Values indicated as bold\* are statistically significant. *OR,* odds ratio; *IPH,* intraplaque haemorrhage. Unadjusted OR indicates univariate analysis, adjusted OR indicates multivariable analysis. Multivariable analyses were corrected for age, sex, surgery year, cerebrovascular symptoms and additional confounders showing p<0.20 association with MetaGRS and the plaque characteristics of interest. Confounders included in various multivariable models can be found in Supplemental Table S2**.** |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Categorical plaque characteristics | Negative FHx(n=911) | Positive FHx(n=640) | Unadjusted OR (95% CI) | Unadjustedp-value |  Adjusted OR(95% CI) | Adjusted p-value |
| Moderate/heavy calcifications | 430/910 (47.3) | 304/638 (47.6) | 1.016 (0.830-1.244) | 0.878 | 0.995 (0.770- 1.286) | 0.971 |
| Moderate/heavy collagen  | 724/908 (79.7) | 500/637 (78.5) | 0.928 (0.723-1.190) | 0.553 | 1.005 (0.991-1.020) | 0.488 |
| Presence of lipid core >10% | 667/911 (73.2) | 467/640 (73.0) | 0.987 (0.786-1.240) | 0.914 | 1.225 (0.950-1.578) | 0.118 |
| Presence of IPH  | 527/909 (58.0) | 389/639 (60.9) | 1.128 (0.918-1.386) | 0.253 | 1.206 (0.922-1.578) | 0.171 |
| Moderate/heavy smooth muscle cells  | 634/908 (69.8) | 438/634 (69.1) | 0.966 (0.775-1.204) | 0.757 | 0.830 (0.649-1.060) | 0.135 |
| Moderate/heavy macrophages  |  501/901 (55.6) | 348/637 (54.6) | 0.961 (0.784-1.179) | 0.705 | 0.912 (0.709-1.174) | 0.476 |
| Continuous plaque characteristics |  |  | **Unadjusted beta****(95% CI)** | **Unadjusted****p-value** | **Adjusted beta****(95% CI)** | **Adjusted p-value** |
| Number of macrophages (median, IQR) | 0.3 [0.9] | 0.4 [1.0] | 0.030 (-0.020-0.079) | 0.240 | 0.033 (- 0.016-0.083) | 0.186 |
| Number of smooth muscle cells (median, IQR) | 1.3 [2.2] | 1.4 [2.5] | 0.042 (-0.024-0.107) | 0.214 | -0.015 (- 0.080-0.051) | 0.661 |
| Microvessels (median, IQR) | 7.6 [8.0] | 6.9 [7.0] | -0.038 (-0.123-0.046) | 0.374 | -0.088 (- 0.188- 0.013) | 0.089 |
| Table S7. Histological carotid plaque characteristics and associations with FHx in the total cohort. Values are displayed as n/total (%), unless otherwise specified. Values indicated as bold\* are statistically significant. *OR,* odds ratio; *IPH,* intraplaque haemorrhage. Unadjusted OR indicates univariate analysis, adjusted OR indicates multivariable analysis. Multivariable analyses were corrected for age, sex, surgery year, cerebrovascular symptoms and additional confounders showing p<0.20 association with MetaGRS and the plaque characteristics of interest. Confounders included in various multivariable models can be found in Supplemental Table S2. |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Female cohort** | **Negative FHx** **(n= 258)** | **Positive FHx** **(n=213)** |  |  |  |  |
| ***Binominal plaque characteristics*** |  |  | **Unadjusted OR (95% CI)** | **p-value** | **Adjusted OR (95% CI)** | **p-value** |
| Moderate/heavy calcifications | 124/258 (48.1) | 123/213 (57.7) | 1.477 (1.025-2.128) | **0.037\*** | *NA* | *NA* |
| Moderate/heavy collagen  | 196/257 (76.3) | 176/212 (83.0) | 1.522 (0.961-2.409) | 0.073 | 1.363 (0.829-2.240) | 0.222 |
| Presence of lipid core >10% | 167/257 (65.0) | 133/213 (62.4) | 0.896 (0.614-1.307) | 0.569 | 1.005 (0.668-1.512) | 0.982 |
| Presence of IPH  | 130/257 (50.6) | 101/213 (47.4) | 0.881 (0.612-1.267) | 0.494 | *NA* | *NA* |
| Moderate/heavy smooth muscle cells  | 186/257 (72.4) | 172/212 (81.1) | 1.641 (1.058-2.547) | **0.027\*** | 1.371 (0.833-2.258) | 0.214 |
| Moderate/heavy macrophages  | 131/255 (51.4) | 95/212 (44.8) | 0.769 (0.533-1.108) | 0.158 | *NA* | *NA* |
| ***Continuous plaque characteristics*** |   |   | **Unadjusted beta (95% CI)** | **p-value**  | **Adjusted beta (95%CI)** | **p-value**  |
| Number of macrophages  | 0.29 [1.01] | 0.31 [0.84] | -0.011 (-0.100-0.077) | 0.803 | -0.021(-0.110-0.067) | 0.638 |
| Number of smooth muscle cells | 1.38 [2.25] | 1.95 [2.86] | 0.171(0.056-0.286) | **0.004\*** | 0.105 (-0.015-0.224) | 0.085 |
| Vessel density  | 6.85 [8.0] | 7.0 [7.0] | 0.047 (-0.107-0.201) | 0.547 | -0.011 (-0.205-0.182) | 0.908 |
|  **Male cohort** | **Negative FHx (n=654)** | **Positive FHx** **(n=427)** |  |  |  |  |
| ***Binominal plaque characteristic*** |  |  | **unadjusted OR (95% CI)** | **p-value** | **Adjusted OR (95%CI)** | **p-value** |
| Moderate/heavy calcifications | 306/652 (46.9) | 181/425 (42.6) | 0.839 (0.656-1.073) | 0.162 | 0.903 (0.662-1.233) | 0.522 |
| Moderate/heavy collagen  | 528/651 (81.1) | 324/425 (76.2) | 0.747 (0.555-1.006) | 0.055 | 0.651 (0.474-0.895) | **0.008\*** |
| Presence of lipid core >10% | 500/654 (76.5) | 334/427 (78.2) | 1.106 (0.826-1.482) | 0.499 | 1.269 (0.926-1.738) | 0.138 |
| Presence of IPH  | 397/652 (60.9) | 288/426 (67.6) | 1.340 (1.037-1.733) | **0.025\*** | 1.295 (0.931-1.800) | 0.124 |
| Moderate/heavy smooth muscle cells  | 448/651 (68.8) | 266/422 (63.0) | 0.773 (0.597-1.000) | 0.050 | 0.692 (0.521-0.918) | **0.011\*** |
| Moderate/heavy macrophages  | 370/646 (57.3) | 253/425 (59.5) | 1.097 (0.856-1.407) | 0.464 | 1.096 (0.808-1.488) | 0.555 |
| ***Continuous*** |   |   | **Unadjusted beta (95% CI)** | **p-value**  | **Adjusted beta (95%CI)** | **p-value**  |
| Number of macrophages | 0.34 [0.93] | 0.39 [1.14] | 0.051 (-0.009-0.111) | 0.096 | 0.057 (-0.003-0.116) | 0.064 |
| Number of smooth muscle cells | 1.27 [2.19] | 1.08 [2.18] | -0.029 (-0.108-0.050) | 0.473 | -0.065 (-0.144-0.013) | 0.102 |
| Vessel density  | 7.67 [7.0] | 6.7 [8.0] | -0.074 (-0.176-0.027) | 0.152 | -0.900 (-0.191-0.011) | 0.081 |
| **Table S8.**  **Associations of histological carotid plaque characteristics and FHx in men and women.**Values are displayed as n/total (%), unless otherwise specified. Values indicated as bold\* are statistically significant. *OR,* odds ratio; *IPH,* intraplaque haemorrhage. Unadjusted OR indicates univariate analysis, adjusted OR indicates multivariable analysis. Multivariable analysis were corrected for age, sex, surgery year, cerebrovascular symptoms and additional confounders showing p<0.20 association with MetaGRS and the plaque characteristics of interest. Confounders included in various multivariable models can be found in Supplemental Table S2.*NA* indicates that multivariable analysis was not available because of limited power. |